
    
      Patients pathologic diagnosed of advanced non-small cell lung cancer, according to NCCN
      non-small cell lung cancer guide line(2015 V1).The patient should receive a 3-day
      cisplatin-based chemotherapy, are randomized divided into two groups, aprepitant group and
      placebo group. In aprepitant group, patients would receive aprepitant(125 mg po at day1, 80
      mg at day2-3) combination with palonosetron and dexamethasone(5mg iv at day1-3, 3.75mg po at
      day4-5). In placebo group patients would receive palonosetron and dexamethasone(5mg iv at
      day1-3, 7.5mg po at day4-5).During the treatment, any grade of nausea and vomiting should be
      recorded in order to evaluate the complete response rate of CINV, other side-effects should
      be recorded.
    
  